Marco Meglio

Neurology experts anticipate groundbreaking clinical trial results in 2025, potentially transforming treatment strategies for various neurological conditions.

Apnimed's AD109 shows promising results in treating obstructive sleep apnea, potentially revolutionizing care for millions with a once-daily oral medication.

Findings show that apathy affects more than half of individuals with LBD, challenging assumptions that it emerges only in later stages and underscoring the need for targeted screening tools and intervention strategies.

Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.

The associate professor of neurology at Mayo Clinic Rochester talked about using artificial intelligence-electrocardiogram at baseline to predict adverse vascular events in patients with migraine. [WATCH TIME: 5 minutes]

The chief program officer at PMD Alliance described an interactive program designed to help health care providers better understand the lived experience of patients with Parkinson disease and related movement disorders. [WATCH TIME: 6 minutes]

In a new study, findings show elevated CSF 14-3-3 protein levels in AQP4-NMOSD, suggesting its potential as a biomarker for neuroaxonal damage and disease severity.

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]

The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]

The FDA-cleared duo devices allow for a more simplified administration of the liquid medicine Hyqvia, reducing the number of steps needed to prepare for the infusion of 2 dual vial units or more.

New study reveals that alixorexton significantly improves wakefulness and reduces daytime sleepiness in narcolepsy type 1, paving the way for phase 3 trials.

Praxis Precision Medicines advances relutrigine for rare epilepsy, achieving FDA breakthrough status and promising results in ongoing clinical trials.

The professor of neurology at Thomas Jefferson University discussed the shifting diagnostic challenges of stiff person syndrome and reviewed current and emerging treatment options. [WATCH TIME: 6 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on progressive multiple sclerosis.

Findings revealed that dry mouth and falls were reported more frequently in patients with Parkinson disease treated with solifenacin in comparison with pelvic floor muscle exercise-based behavioral therapy.

FDA halts Sarepta's Elevidys gene therapy distribution after three patient deaths, prioritizing safety amid ongoing clinical trial evaluations.

At AHS 2025, the assistant professor of neurology at the Icahn School of Medicine at Mount Sinai highlighted the challenges LGBTQIA+ individuals may face in migraine care. [WATCH TIME: 6 minutes]

Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings.

The assistant professor of neurology at Wake Forest Baptist Atrium Health discussed emerging research on how breast size may contribute to headache disorders, including migraine. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Stewart Tepper, MD. [LISTEN TIME: 26 minutes]

A recent research letter emphasized that meningitis could be a possible early manifestation of MOG antibody–associated disease, according to results previously published in an international study.

A recent survey revealed significant variability in treatment decisions for pediatric MOGAD, highlighting gaps in knowledge and the potential need for improved clinical guidelines.

Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.

Recent findings suggest that laser interstitial thermal therapy could offer patients with drug-resistant mesial temporal lobe epilepsy a minimally invasive and safe therapeutic option.

A study links high ultraprocessed food consumption to increased risks of nonmotor Parkinson's disease symptoms, highlighting potential dietary impacts on neurodegeneration.

The professor of neuroscience at Harvard Medical School highlighted gaps in headache care access, provider training, and medication availability in regions like Kenya and the Philippines. [WATCH TIME: 5 minutes]

Nester Tomycz, MD, director of neurosurgical pain division at Allegheny General Hospital, discussed emerging neurosurgerical approaches for chronic pain, with a focus on neuromodulation, patient selection, and non-opioid treatment pathways.

The professor and chair of neuroscience at UT Southwestern Medical Center offered an overview on his keynote lecture presented at AHS 2025 on the circadian clock in relation to headache.

A recent study highlighted key unmet needs and barriers that may lead to preventable nursing home placements among Black, Hispanic/Latino, and White patients living with dementia.

Emmanuel During, MD, an associate professor of neurology at the Icahn School of Medicine at Mount Sinai, discussed the external validation of an actigraphy-based classifier for diagnosing iRBD and its implications for scalable neurodegenerative screening.